Focus Shifts to Europe as Gilead Backs Away From Arthritis-Drug Partnership
Order Reprints Text size JAK inhibitors such as filgotinib block enzymes that cause much of the mischief in autoimmune diseases. Dreamstime Gilead Sciences plunked down $5 billion last year to partner with Belgium’s Galapagos on treatments for autoimmune disorders such as arthritis and Crohn’s disease. Galapagos’s lead drug candidate was filgotinib, a so-called JAK inhibitor undergoing clinical trials in the U.S. and Europe. But in August of this year, the U.S. Food and Drug Administration rebuffed the partners’ application for approval to market...
Source: barrons.com